Study Assesses Epidemiology of Carbapenem-resistant Enterobacteriaceae
the ONA take:
Most carbapenem-resistant enterobacteriacecae (CRE) cases in the United States are associated with a high prevalence of prior hospitalizations or indwelling devices and discharge to long-term care settings, a study published in JAMA has shown.
Because CRE cases have been increasingly reported worldwide as a cause of infection with high-mortality rates, researchers sought to determine the population-based CRE incidence in seven US geographical areas.
For the study, researchers analyzed case records from persons living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon.
Results showed that the incidence of CRE was 2.93 per 100,000 people. Researchers also found that the majority of CRE cases were in women.
CRE cases were significantly higher than predicted for Georgia, Maryland, and New York, while Colorado, New Mexico, and Oregon had significantly fewer cases than predicted.
The study demonstrated that most CRE cases occurred in patients with prior hospitalizations or indwelling devices, and the majority of admitted cases results in discharge to a long-term care setting.
The carbapenem antibiotic class includes imipenem, meropenem, doripenem, and ertapenem. Extended-spectrum cephalosporin-resistant enterobacteriaceae are typically susceptible to carbapenems except ertapenem.
Most carbapenem-resistant enterobacteriacecae (CRE) cases associated with a high prevalence of prior hospitalizations.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|